Showing results (881-890 of 4,634) with videos related to

Sort By:
Pageof 464
Anti-Cancer Drugs|December 1, 2022
Exosomal circ-ADRM1 promotes lung adenocarcinoma progression and induces macrophage M2 polarization through regulating MMP14 mRNA and proteinJun Qian, Jie Li, Haitao Ma, et al.
Anti-Cancer Drugs|January 15, 2019
Rectovaginal fistula during treatment with axitinib in a patient with renal cell carcinoma: a case report and review of the literatureOlga Nigro, Alessia Pastore, Tiziana Tartaro, et al.
Anti-Cancer Drugs|September 15, 2020
Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experienceSilvia Mezi, Giulia Pomati, Andrea Botticelli, et al.
Anti-Cancer Drugs|September 15, 2020
LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma: feasibility, safety and pharmacokinetic studyGeert Maleux, Hans Prenen, Thomas Helmberger, et al.
Anti-Cancer Drugs|September 2, 2020
Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective studyShu Yazaki, Jun Hashimoto, Shin Ogita, et al.
Anti-Cancer Drugs|September 2, 2020
The positive correlation between drug addiction and drug dosage in vemurafenib-resistant melanoma cells is underpinned by activation of ERK1/2-FRA-1 pathwayMinla Rao, Benyan Shi, Yuan Yuan, et al.
Anti-Cancer Drugs|October 10, 2020
Dabrafenib and trametinib induced pancreatitis: a case report and review of the literatureFrancesca R Ogliari, Giovanni L Rodolfo Masera, Rossana Gueli, et al.
Anti-Cancer Drugs|January 4, 2021
Evodiamine inhibits vasculogenic mimicry in HCT116 cells by suppressing hypoxia-inducible factor 1-alpha-mediated angiogenesisDi Zeng, Peng Zhou, Rong Jiang, et al.
Anti-Cancer Drugs|July 15, 2021
Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18-25 kinase domain duplication: report of two casesLong-Dan Zhang, Han Gao, Shou-Ming Qin, et al.
Anti-Cancer Drugs|July 7, 2021
Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patientsPo-Hsin Lee, Kun-Chieh Chen, Kuo-Hsuan Hsu, et al.
Pageof 464